News for Healthier Living

Enhanced CAR T Cell Therapy Offers New Strategy for Lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. The findings, led by researchers in the Perelman School of Medicine at the University of Pennsylvania, were published today in the New England Journal of Medicine.

May 7, 2025


May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025

April 30 2025

April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025